In this context, a report by Byun S et al. suggests USP8 as a novel therapeutic target for overcoming gefitinib resistance in lung cancer, specifically involving USP8 in EGF-R signaling (Byun et al., 2013). Here, USP8 is linked to lung carcinoma.